Sound Shore Management Inc CT Cuts Stake in Incyte Corporation $INCY

Sound Shore Management Inc CT decreased its position in Incyte Corporation (NASDAQ:INCY) by 25.5% during the 3rd quarter, Holdings Channel reports. The fund owned 849,856 shares of the biopharmaceutical company’s stock after selling 290,201 shares during the quarter. Sound Shore Management Inc CT’s holdings in Incyte were worth $72,076,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. purchased a new stake in Incyte in the 3rd quarter valued at approximately $26,000. Root Financial Partners LLC acquired a new stake in shares of Incyte in the 3rd quarter valued at approximately $28,000. Quent Capital LLC purchased a new stake in shares of Incyte in the third quarter valued at approximately $30,000. FNY Investment Advisers LLC acquired a new position in Incyte during the second quarter worth $27,000. Finally, MUFG Securities EMEA plc purchased a new position in Incyte in the second quarter worth $32,000. 96.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

INCY has been the topic of several research analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of Incyte in a research report on Thursday, January 22nd. Mizuho set a $121.00 price objective on shares of Incyte and gave the stock an “outperform” rating in a report on Monday, December 8th. Guggenheim upgraded shares of Incyte from a “neutral” rating to a “buy” rating and set a $125.00 target price on the stock in a research report on Monday, November 3rd. HC Wainwright reiterated a “buy” rating and set a $135.00 price target on shares of Incyte in a research report on Wednesday. Finally, Piper Sandler raised their price objective on Incyte from $102.00 to $110.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $103.94.

Incyte Price Performance

INCY stock opened at $98.84 on Thursday. The stock’s 50 day moving average price is $101.75 and its 200 day moving average price is $93.81. The firm has a market cap of $19.40 billion, a P/E ratio of 15.42, a PEG ratio of 0.60 and a beta of 0.82. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.13 and a current ratio of 3.23. Incyte Corporation has a 1 year low of $53.56 and a 1 year high of $112.29.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The company had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The business’s revenue was up 27.8% compared to the same quarter last year. During the same period last year, the firm earned $1.43 earnings per share. On average, sell-side analysts expect that Incyte Corporation will post 4.86 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Thomas Tray sold 2,774 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $100.00, for a total transaction of $277,400.00. Following the transaction, the insider owned 22,973 shares of the company’s stock, valued at approximately $2,297,300. This represents a 10.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Steven H. Stein sold 20,105 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $102.51, for a total transaction of $2,060,963.55. Following the sale, the executive vice president owned 63,129 shares in the company, valued at approximately $6,471,353.79. This trade represents a 24.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 95,225 shares of company stock valued at $9,519,745 in the last 90 days. Company insiders own 17.80% of the company’s stock.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Management laid out a 10–13% revenue growth target for 2026 and emphasized pipeline expansion and upcoming product launches, which supports medium‑term revenue upside if clinical readouts and launches progress as planned. Article Title
• Positive Sentiment: Q4 product sales topped expectations (Jakafi and Opzelura contributed to a ~28% revenue jump), showing demand strength that supports near-term cash flow. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy and $135 target (and other bullish research notes highlighted long‑term revenue durability), which could attract buyers looking past the guidance miss. Article Title
• Neutral Sentiment: Company provided an earnings‑call transcript and slide deck; management framed growth “beyond Jakafi,” useful for investors parsing product mix and timing of launches. Article Title
• Neutral Sentiment: Incyte completed a real‑estate sale (Wilmington Bracebridge towers), a non‑core cash/asset move that modestly improves balance sheet flexibility but is unlikely to materially alter operating outlook. Article Title
• Neutral Sentiment: Analyst coverage is mixed/pragmatic — some trims to targets but others reaffirm buys; expect continued analyst debate while Jakafi patent timing and Opzelura trajectory become clearer. Article Title
• Negative Sentiment: EPS missed estimates (Q4 EPS $1.80 vs. ~$1.96 expected) and management issued a softer 2026 revenue forecast; that guidance miss is the primary driver of today’s pullback. Article Title
• Negative Sentiment: Royal Bank of Canada lowered its price target (to $92) and commentary flagged downside vs. current levels, which may weigh on sentiment until guidance clarity improves. Article Title
• Negative Sentiment: Regulatory risk: emerging “Most Favored Nation” drug‑pricing policies and looming Jakafi patent expiry remain material downside risks to margin and revenue durability. Article Title

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.